ALKS FINANCIAL STATEMENTS

Alkermes Plc — balance sheet, income statement and cash flow trends

ALKSAlkermes Plc

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue1.6 B $+3.2%

Gross Profit1.4 B $+5.9%

Operating Income191.9 M $-50.9%

EBITDA276.4 M $-40.8%

Net Income152.7 M $-56.7%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
ALKS	3.2%	86.6%	17.7%	9.8%
ROVI	-3.4%	63.2%	27.0%	17.8%
BHC	-9.9%	75.9%	60.0%	-13.5%
MRK	-1.7%	58.5%	28.5%	12.1%
ECILC	-2.3%	34.3%	14.8%	-3.6%
GENIL	16.3%	23.4%	14.3%	4.0%
Industry median	7.5%	60.6%	18.2%	4.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
ALKS	3.2%	86.6%	17.7%	9.8%
HIMS	32.8%	67.6%	1.3%	-0.6%
LQDA	1,936.7%	91.8%	18.7%	7.7%
LNTH	0.6%	60.5%	30.6%	18.0%
ELAN	10.5%	49.4%	15.6%	-4.9%
AMRX	7.6%	38.7%	20.6%	4.0%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity1.8 B $41%
Current Liabilities599.5 M $14%
Long-term Liabilities1.9 B $45%

Key Figures

YoY change

Total Assets4.3 B $+104.5%

Total Liabilities2.5 B $+339.4%

Total Equity1.8 B $+15.9%

Cash & ST Investments511.9 M $-42.1%

Total Debt1.6 B $+2,034.4%

Net Debt1.2 B $—

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
ALKS	2.27	90.3%	3.87	41.1%
ROVI	3.66	17.0%	0.09	72.8%
BHC	1.32	-1,010.0%	3.71	-8.4%
MRK	1.51	40.5%	1.38	56.0%
ECILC	1.73	5.9%	-0.10	81.0%
GENIL	1.33	41.0%	1.10	52.6%
Industry median	2.22	46.3%	1.24	45.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
ALKS	2.27	90.3%	3.87	41.1%
HIMS	1.69	253.7%	12.68	19.7%
LQDA	2.22	170.2%	-0.71	27.0%
LNTH	2.83	51.6%	0.27	51.7%
ELAN	2.16	61.4%	4.66	49.2%
AMRX	2.47	-5,938.0%	3.99	-1.3%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow256.2 M $-50.4%

Capital Expenditures34.4 M $-2.3%

Free Cash Flow221.8 M $-53.9%

Dividends Paid——

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
ALKS	16.4%	14.2%	2.2%	167.8%
ROVI	24.4%	15.5%	8.9%	137.0%
BHC	16.2%	11.3%	4.9%	-119.7%
MRK	20.0%	11.5%	8.5%	165.6%
ECILC	13.9%	16.1%	7.1%	-391.0%
GENIL	6.4%	-6.7%	4.8%	162.4%
Industry median	15.2%	11.6%	2.5%	84.3%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
ALKS	16.4%	14.2%	2.2%	167.8%
HIMS	12.0%	3.2%	8.8%	-2,143.3%
LQDA	16.7%	14.3%	2.4%	215.1%
LNTH	26.4%	24.0%	2.3%	146.1%
ELAN	11.8%	6.4%	5.4%	-238.4%
AMRX	10.0%	6.7%	3.2%	248.3%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on ALKS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.